No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MFA MFA Financial
- 10.430
- +0.150+1.46%
Close Apr 19 16:00 ET
- 10.310
- -0.120-1.15%
Post 17:19 ET
1.06BMarket Cap22.67P/E (TTM)
10.480High10.210Low528.84KVolume10.240Open10.280Pre Close5.49MTurnover0.52%Turnover Ratio22.67P/E (Static)102.08MShares11.41052wk High0.56P/B1.05BFloat Cap7.90852wk Low1.40Dividend TTM100.95MShs Float20.887Historical High13.42%Div YieldTTM2.62%Amplitude0.826Historical Low10.386Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | JMP Securities Reiterates Market Outperform on MFA Finl, Maintains $12.5 Price Target
MFA Finl Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 20.48% JMP Securities → $12.5 Reiterates Market Outperform → Market Outperform 12/13/2023 15.66
MFA Financial, Inc.'s (NYSE:MFA) Institutional Investors Lost 9.0% Over the Past Week but Have Profited From Longer-term Gains
Key Insights Given the large stake in the stock by institutions, MFA Financial's stock price might be vulnerable to their trading decisions The top 20 shareholders own 50% of the company Ownership
Express News | MFA Financial Inc: Intends to Apply to List Notes on New York Stock Exchange Under Symbol "Mfao"
Express News | MFA Financial Inc: Pricing of an Underwritten Public Offering of $75 Mln Aggregate Principal Amount of Its 9.000% Senior Notes Due 2029
Express News | MFA Financial, Inc. Announces Pricing of Public Offering of Senior Notes
Comments
2
ColumnsToday's Pre-Market Stock Movers: AAPL, BIIB, OCGN, MNMD and More
Gapping up
In reaction to earnings/guidance:
• $Thor Industries(THO.US$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US$+76.8% (in response with BIIB)
• $Biogen(BIIB.US$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US$ +9.3% (en...
In reaction to earnings/guidance:
• $Thor Industries(THO.US$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US$+76.8% (in response with BIIB)
• $Biogen(BIIB.US$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US$ +9.3% (en...
15
1
loading...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg